Application of CRISPR/Cas9 Technology to HBV

More than 240 million people around the world are chronically infected with hepatitis B virus (HBV). Nucleos(t)ide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (c...

Full description

Saved in:
Bibliographic Details
Main Authors: Guigao Lin, Kuo Zhang, Jinming Li
Format: Artigo
Language:Inglês
Published: MDPI AG 2015-11-01
Series:International Journal of Molecular Sciences
Subjects:
CRISPR/Cas9
HBV
cccDNA
antiviral
Online Access:http://www.mdpi.com/1422-0067/16/11/25950
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items